FDA sends 23 warning letters about drug ads

被引：0

|

作者：

Dorey, E

机构：

来源：

CHEMISTRY & INDUSTRY | 2005年 / 03期

关键词：

D O I：

暂无

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

引用

收藏

页码：6 / 6

页数：1

相关论文

共 50 条

[1] FDA Issues Warning Letters About Claims Regarding Lipodissolve
不详
[J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (07) : 874 - 874
[2] FDA issues warning letters about unapproved eye disorder therapies
[J]. Reactions Weekly, 2023, 1975 (1) : 6 - 6
[3] Study examines FDA warning letters about medical devices from 2009
Yang, Hongli
Hyman, William A.
[J]. Biomedical Instrumentation and Technology, 2010, 44 (04): : 336 - 338
[4] FDA warning letters give additional details
不详
[J]. JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2009, 235 (10): : 1117 - 1117
[5] FDA issues new clinical research warning letters
不详
[J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2002, 50 (05) : 344 - 345
[6] Responding to FDA-483s and warning letters
Chesney, DL
Kelly, AE
[J]. BIOPHARM-THE APPLIED TECHNOLOGIES OF BIOPHARMACEUTICAL DEVELOPMENT, 1998, 11 (10): : 26 - 29
[7] The value of fda 483s and warning letters
[J]. Pharmaceutical Technology, 2021, 45 (07)
[8] A Communication Effectiveness Study of the FDA GMP Warning Letters
Bao, Yiyi
Zheng, Qiang
[J]. JOURNAL OF PHARMACEUTICAL INNOVATION, 2024, 19 (03)
[9] PRESCRIPTION DRUG ADS PUT FDA ON THE SPOT
KOLATA, G
[J]. SCIENCE, 1983, 220 (4595) : 387 - 388
[10] A Longitudinal Examination of FDA Warning and Untitled Letters Issued to Pharmaceutical Companies for Violations in Drug Promotion Standards
Limbu, Yam B.
McKinley, Christopher
Temperini, Valerio
[J]. JOURNAL OF CONSUMER AFFAIRS, 2019, 53 (01) : 3 - 23

← 1 2 3 4 5 →